Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy
Objective: To develop population pharmacokinetic (PK) models for levodopa (LD) and carbidopa (CD) following subcutaneous (SC) infusion, including adjunct oral LD/CD administration. Background: ND0612 is…A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Interim Results
Objective: Evaluate the long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s…The exosomal a-syn filaments can be a novel biomarker of Parkinson’s disease
Objective: This study is aimed to investigate whether the number of exosomes, the amount of total or exosomal a-synuclein (a-syn) filaments in serum can serve as…Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson’s Disease
Objective: To assess serum pharmacokinetics (PK) and cerebrospinal fluid (CSF) concentrations of nilotinib as well as CSF biomarker changes in NILO-PD study. Background: Several cell…Types of Pain in Parkinson`s Disease Patients
Objective: To present the characteristics of four different types of pain in Parkinson`s disease (PD) patients. Background: Neurodegeneration can cause a nociceptive disturbances at many…Deep Brain Stimulation impact on Social and Occupational Function in Parkinson’s Disease with Early Motor Complications
Objective: To investigate the effect of DBS compared with BMT on social, psychosocial and occupational functioning in PD patients ≤ 60 years of age with…Effect of Lactobacillus casei supplementation on clinical response, gut microbiota and faecal metabolites in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial
Objective: To evaluate the effect of Lactobacillus casei strain Shirota (LcS) supplementation on symptoms, gut microbiota and faecal metabolites in patients with Parkinson's disease (PD).…A Parkinson’s disease dog providing therapeutic intervention in Parkinson’s disease
Objective: To report a case of Parkinson’s disease gait impairment which responded favourably to intervention with an assistance dog. Background: Gait abnormalities including freezing of…Efficacy and security starting safinamide treatment with 100 mg/day in Parkinson’s disease
Objective: Evaluating the efficacy and security starting safinamide treatment with 100 mg/day in PD Background: Safinamide has a unique dopaminergic and non-dopaminergic mode of action…Effectiveness of Carbidopa/Levodopa Enteral Suspension (CLES) in Advanced Parkinson’s Disease (APD) Patients with Moderate to Severe Fatigue: Sub-group Analysis from PROviDE study
Objective: To examine the effect of CLES at 12 months of follow-up in APD patients with moderate to severe fatigue. Background: Fatigue, one of the…
- « Previous Page
- 1
- …
- 116
- 117
- 118
- 119
- 120
- …
- 149
- Next Page »